Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

Rhea-AI Summary

On March 21, 2023, Generation Bio (Nasdaq:GBIO) announced its participation in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines. The virtual event will occur on March 28 at 10:00 a.m. ET.

Generation Bio is focused on developing genetic medicines for rare and prevalent diseases. Their innovative platform features closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a proprietary cell-free rapid enzymatic synthesis (RES) process. This technology aims to provide durable, redosable treatments potentially capable of producing hundreds of millions of doses, thus broadening access to genetic therapies globally.

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in the Novel LNPs Targeting Diverse Tissues panel at the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines, which will take place virtually on Tuesday, March 28^th at 10:00 a.m. ET.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. This approach is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit www.generationbio.com. 

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638

FAQ

What is the date of the BMO Biopharma Spotlight Series involving GBIO?

The BMO Biopharma Spotlight Series featuring Generation Bio will take place on March 28, 2023, at 10:00 a.m. ET.

What is the main focus of Generation Bio's technology?

Generation Bio focuses on developing genetic medicines using their non-viral platform that includes closed-ended DNA and a unique delivery system for durable treatments.

What innovative process does Generation Bio use for manufacturing?

Generation Bio employs a proprietary cell-free rapid enzymatic synthesis (RES) process to produce closed-ended DNA, enhancing their manufacturing capabilities.

What are the key components of Generation Bio's genetic medicine platform?

The key components include closed-ended DNA (ceDNA), cell-targeted lipid nanoparticle delivery system (ctLNP), and the RES manufacturing process.

How does Generation Bio aim to improve the delivery of genetic medicines?

Generation Bio aims to improve delivery through a scalable manufacturing process that can support the production of hundreds of millions of doses.